Form 4: Immuneering Corp CEO Benjamin Zeskind Boosts Stake with $50K Stock Purchase

Immuneering Corp's President and CEO, Benjamin J. Zeskind, has increased his direct beneficial ownership in the company by purchasing 21,000 shares of Class A Common Stock.

Summary

• Benjamin J. Zeskind, President and CEO, Director, and 10% Owner of Immuneering Corp (IMRX), purchased 21,000 shares of Class A Common Stock.
• The transaction occurred on June 18, 2025, at a weighted average price of $2.3878 per share.
• This purchase increases his direct beneficial ownership to 2,302,852 shares.
• Additionally, Dr. Zeskind indirectly beneficially owns 894,927 shares through the Benjamin J. Zeskind 2020 Family Trust.

Sentiment

Score: 8

Explanation: The purchase of company stock by the President and CEO indicates strong confidence in the company's prospects, which is generally viewed as a positive signal by the market.

Positives

• The President and CEO, Benjamin J. Zeskind, purchased 21,000 shares of company stock, indicating strong confidence in Immuneering Corp's future prospects.
• The purchase was made at a weighted average price of $2.3878 per share, representing a direct investment of approximately $50,143.80 by a key insider.
• This transaction increases the CEO's direct beneficial ownership to 2,302,852 shares, aligning his interests further with those of shareholders.

Negatives

• No negative information was disclosed in this Form 4 filing, which is solely for reporting changes in beneficial ownership.

Risks

• This Form 4 filing does not contain information regarding company-specific risks. It is a disclosure of an insider transaction.

Future Outlook

This Form 4 filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports an insider purchase by the CEO of Immuneering Corp, a biotechnology company. Insider buying, particularly by top executives, is often viewed by investors as a positive signal, indicating management's confidence in the company's future performance and valuation within the competitive biotechnology sector.

Related Party Transactions

• The indirect beneficial ownership of 894,927 shares is held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee. This constitutes a related party holding for beneficial ownership reporting purposes.

Stakeholder Impact

• Shareholders: The purchase by the CEO may be interpreted as a strong vote of confidence, potentially leading to increased investor interest and positive sentiment towards the stock.
• Employees: While not directly impacted, a CEO's increased stake can signal stability and belief in the company's long-term vision.

Next Steps

• This Form 4 filing is a transactional disclosure and does not outline specific future actions, events, or milestones for the company.

Key Dates

Recommendation

Keywords

Immuneering Corp, IMRX, Benjamin J. Zeskind, insider trading, stock purchase, CEO, director, beneficial ownership, SEC Form 4, Class A Common Stock